News › Industry News

Allergan Licenses Rights to Medytox Candidates, in Up-to-$362M Deal

June 25, 2018

In a deal that could net Medytox up to $362 million, the Seoul-based company will license to Allergan exclusive global rights outside Korea to develop and commercialize unspecified neurotoxin product candidates now in development phases, including a potential liquid-injectable product, the companies said today.
In return for the license, Allergan will pay Medytox $65 million up front, up to $116.6 million in potential payments tied to undisclosed development milestones, and another up to $180.5 million in potential payments tied to undisclosed commercialization milestones, plus royalties on product sales.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Pledges Donation for New Allē Member Referrals During Skin Cancer Awareness Month
    • Dermalogica Launches FDA-Cleared PRO Pen Microneedling System
    • Regenerative Aesthetics Is Evolving. Are You Keeping Up?
    • Influx Marketing Introduces Growthstack, a New All-In-One Growth Platform Built for Med Spas
    • AbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE